S&P Futures
4,140.75-14.75(-0.35%)Dow Futures
33,841.00-117.00(-0.34%)Nasdaq Futures
13,861.00-36.25(-0.26%)
PharmaCyte Biotech, Inc. (PMCB)
Chart Events
Performance Outlook
| Previous Close | 0.0164 |
| Open | 0.0165 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0150 - 0.0165 |
| 52 Week Range | 0.0045 - 0.0370 |
| Volume | 3,664,583 |
| Avg. Volume | 18,169,316 |
| Market Cap | 36.492M |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0020 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
PharmaCyte Biotech Successfully Completes 1 Year Stability Study
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the twelve-months product stability testing required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final clinical trial product. This product will be used in the company’s planned clinical trial in locally advanced, inoperable pancreatic cancer upon the FDA lifting the clinical hold on PharmaCyte’s Investigational New Drug Application (IND).
- Business Wire
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product
PharmaCyte Biotech begins DNA sequence and stability studies in response to the FDA's requests for PharmaCyte's clinical trial product.
- Business Wire
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
PharmaCyte Biotech begins testing of its clinical trial product in response to the FDA's recommendations to lift the clinical hold.
